- Home
- ACRS vs BSL Comparison
ACRS vs BSL Comparison
Compare ACRS & BSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- BSL
- Stock Information
- Founded
- ACRS 2012
- BSL 2010
- Country
- ACRS United States
- BSL United States
- Employees
- ACRS N/A
- BSL N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- BSL Trusts Except Educational Religious and Charitable
- Sector
- ACRS Health Care
- BSL Finance
- Exchange
- ACRS Nasdaq
- BSL Nasdaq
- Market Cap
- ACRS 170.9M
- BSL 186.5M
- IPO Year
- ACRS 2015
- BSL N/A
- Fundamental
- Price
- ACRS $1.53
- BSL $14.11
- Analyst Decision
- ACRS Strong Buy
- BSL
- Analyst Count
- ACRS 7
- BSL 0
- Target Price
- ACRS $11.67
- BSL N/A
- AVG Volume (30 Days)
- ACRS 1.2M
- BSL 71.9K
- Earning Date
- ACRS 05-06-2025
- BSL 01-01-0001
- Dividend Yield
- ACRS N/A
- BSL 9.55%
- EPS Growth
- ACRS N/A
- BSL N/A
- EPS
- ACRS N/A
- BSL N/A
- Revenue
- ACRS $18,720,000.00
- BSL N/A
- Revenue This Year
- ACRS N/A
- BSL N/A
- Revenue Next Year
- ACRS N/A
- BSL N/A
- P/E Ratio
- ACRS N/A
- BSL N/A
- Revenue Growth
- ACRS N/A
- BSL N/A
- 52 Week Low
- ACRS $0.95
- BSL $12.19
- 52 Week High
- ACRS $5.17
- BSL $14.56
- Technical
- Relative Strength Index (RSI)
- ACRS 28.64
- BSL 42.72
- Support Level
- ACRS $1.57
- BSL $14.07
- Resistance Level
- ACRS $1.78
- BSL $14.23
- Average True Range (ATR)
- ACRS 0.10
- BSL 0.09
- MACD
- ACRS 0.02
- BSL 0.02
- Stochastic Oscillator
- ACRS 17.74
- BSL 33.33
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About BSL Blackstone
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It also invests in second-lien loans and high yield bonds and employs financial leverage, which may increase the risk to the Fund.